ArriVent BioPharma (AVBP) Cash from Operations (2023 - 2026)
ArriVent BioPharma (AVBP) posted Cash from Operations of 41892000.0 for Q1 2026, down 36.64% sequentially from 30658000.0 in Q4 2025, and up 38.4% YoY from 30268487.7 in Q1 2025.
ArriVent BioPharma (AVBP) Cash from Operations (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Cash from Operations for 4 years, with the latest figure at 41892000.0 in Q1 2026.
- Quarterly Cash from Operations rose 38.4% year-over-year to 41892000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 134472000.0 (down 12.44% YoY) and the FY2025 annual result came in at 160588000.0, down 128.72% from the prior year.
- Cash from Operations declined to 41892000.0 in Q1 2026 per AVBP's latest filing, from 30658000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 8606000.0 in Q2 2023 and troughed at 68008000.0 in Q1 2025.
- A 4-year average of 25271846.15 and a median of 18628000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations tumbled 265.08% in 2025, then surged 38.4% in 2026.
- Over 4 years, Cash from Operations stood at 14913000.0 in 2023, then fell by 8.31% to 16152000.0 in 2024, then sank by 89.81% to 30658000.0 in 2025, then tumbled by 36.64% to 41892000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 41892000.0, 30658000.0, and 35798000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | -39.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -39.58 Mn |
| Jun 30, 2026 | -39.58 Mn |
| Mar 31, 2026 | -41.89 Mn |
| Mar 31, 2026 | -41.89 Mn |
| Dec 31, 2025 | -30.66 Mn |
| Dec 31, 2025 | -30.66 Mn |
| Sep 30, 2025 | -35.80 Mn |
| Sep 30, 2025 | -35.80 Mn |
| Jun 30, 2025 | -26.12 Mn |
| Jun 30, 2025 | -26.12 Mn |
| Mar 31, 2025 | -68.01 Mn |
| Mar 31, 2025 | -68.01 Mn |
| Dec 31, 2024 | -16.15 Mn |
| Dec 31, 2024 | -16.15 Mn |
| Sep 30, 2024 | -16.35 Mn |
| Sep 30, 2024 | -16.35 Mn |
| Jun 30, 2024 | -19.09 Mn |
| Jun 30, 2024 | -19.09 Mn |
| Mar 31, 2024 | -18.63 Mn |
| Mar 31, 2024 | -18.63 Mn |